RecruitingHepatic EncephalopathyCirrhosis
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
Eligible age
18–99 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This research is studying how a food product (resistant potato starch) which is a dietary supplement made from potato starch affects the gut bacteria of people with cirrhosis and hepatic encephalopathy. The researchers in this study want to understand how potato starch works in the subject's body and how the body will react to it. Along with taking the study product participants health-related information and stool will be collected for this research study.
Sponsor: Mayo Clinic
You may qualify if…
- ✓ Able to provide consent, with signed and dated informed consent form.
- ✓ Stated willingness to comply with all study procedures and availability for the duration of the study.
- ✓ Diagnosis of cirrhosis based on liver biopsy, imaging, or evidence of clinical decompensation.
- ✓ History of at least one episode of overt Hepatic Encephalopathy (HE) in the last year.
- ✓ Defined by West Haven Criteria Grades II to IV
- ✓ Can be precipitated Hepatic Encephalopathy (HE) episode.
- ✓ Sexually active women of childbearing potential enrolled in the study must agree to use a highly-effective method of contraception (defined in the protocol) for the duration of the study.
You may not qualify if…
- ✕ Hospitalization in the last 4 weeks
- ✕ Current refractory ascites (requiring large volume paracentesis to manage ascites)
- ✕ Gut-absorbable or intravenous antibiotic therapy in the last 4 weeks (rifaximin is permitted)
- ✕ Anticipated antibiotics in the coming 4 weeks
- ✕ Use of lactulose in the last 4 weeks
- ✕ Alcohol or illicit drug intake in the last 4 weeks
- ✕ By history
- ✕ Alcohol use will be characterized as \>1 alcoholic drink / week
Where it's recruiting
Minnesota
Rochester
Source: ClinicalTrials.gov · NCT06425380 · last updated 2026-01-30